Measurement of cardiac output is an integral part of patient management in the intensive care unit. FloTrac/Vigileo is a continuous cardiac output monitoring device that does not need re-calibration. However, its reliability has been questioned in some studies, especially involving surgical patients. In this study, we evaluated the comparability of FloTrac/Vigileo and transthoracic Doppler echocardiography in 53 critically ill patients requiring continuous cardiac output monitoring. Most of these patients had septic or cardiogenic shock. Cardiac output was measured by both FloTrac/Vigileo and transthoracic Doppler echocardiography. The bias and precision (mean and SD) between the two devices was 0.35±1.35 l/minute. The limits of agreement were -2.3 to 3.0 l/minute (%error=49.3%). When patients with irregular heart rhythms and aortic stenosis were excluded, the bias and precision was 0.02±0.80 l/minute (n=42). The limits of agreement were -1.55 to 1.59 l/minute (%error=29.5%). Patient demographics (body surface area, gender and age) did not affect the bias, but there was a mild tendency for FloTrac/ Vigileo to register a higher cardiac output at high heart rates. Changes in cardiac output for two consecutive days correlated well between the two methods (r=0.86; P <0.001). In summary, with the exceptions of patients with irregular heart rhythms and significant aortic stenosis, FloTrac/Vigileo is clinically comparable to transthoracic Doppler echocardiography in cardiac output measurements in critically ill patients.
Maintaining adequate tissue perfusion with the aim of optimising oxygen delivery is a primary focus in managing critically ill patients. Cardiac output (CO) is often used as a surrogate parameter for haemodynamic assessment, assessment of cardiac function and guiding treatment. Over the past 30 years, the pulmonary artery catheter (PAC) thermodilution technique has been regarded as the 'gold standard' for CO measurement due to its relative accuracy and practicality. However, it is known that PAC thermodilution suffers from imprecision arising from possible intracardiac shunts, tricuspid regurgitation, increased pleural pressure (as in mechanical ventilation) and low cardiac output states 1, 2 . The technical errors in injection of cold saline for calibration induce further imprecision in the method 3 . It is therefore said that when one seeks to compare a new CO measuring method with PAC thermodilution one is not comparing a 'gold standard' but two different methods each with their own level of imprecision 4 .
Finding a simple and accurate way to measure CO is still a challenge to modern medicine. A recently introduced CO measuring device, based on arterial pressure waveform analysis (arterial pressure-based CO, or APCO), promised to deliver accurate and continuous CO measurements without external calibration and re-calibration (FloTrac/Vigileo™, Edwards Lifesciences, Irvine, CA, USA) 5 . The cardiac output is calculated from information such as pulse rate and pulsatility from the arterial pressure waveform after correction for body height and weight, age and gender. A number of factors are known to affect the device's accuracy, including aortic valve pathology and irregular pulse 6, 7 . Studies to date have presented a mixed picture on the accuracy and effectiveness of this technique in the critically ill patient.
Transthoracic echocardiography (TTE) is a noninvasive procedure and has become a standard modality in intensive care units. TTE calculates the CO (CO Echo ) from heart rate and stroke volume. The stroke volume is commonly calculated from the left ventricular outflow tract (LVOT) crosssectional area and the blood flow velocity through it. Compared to the APCO, CO Echo does not rely on predictive mathematical modelling and is therefore accurate in most circumstances. One drawback of TTE is that it does not provide continuous CO monitoring -only a 'snapshot' of CO during the study.
To facilitate the management and treatment processes in intensive care units, CO measurements need to be comparable between different devices. The aims of this study are to examine the comparability of APCO and CO Echo , to identify if the bias between the two devices can be affected by demographic data and heart rate, and to examine the synergy of these two methods in the critical care setting.
METHODS

Patients
A total of 59 patients who underwent APCO monitoring were recruited over a period of eight months. These patients required continuous CO monitoring as part of their management to optimise treatment. Six patients were excluded from the study due to poor TTE images or insufficient data collection. Among the remaining 53 patients, five had atrial fibrillation during the study and six had aortic valve pathology (five severe aortic stenosis and one prosthetic aortic valve stenosis). These patients were excluded in the final analysis as aortic stenosis and irregular pulse are known to affect the arterial pulse characteristics 6, 7 . The study protocol was approved by the institution's ethics committee and written consent was obtained from the patients' next-of-kin.
Study protocol
Once the FloTrac/Vigileo CO monitors were connected to the patients, TTEs were performed by experienced sonographers within the first six hours and then again after 24 hours, unless the FloTrac/ Vigileo monitor was disconnected from the patient or the patient developed arrhythmias (defined in this study as irregular heart rhythm such as atrial fibrillation or frequent ectopics). The APCO data was collected at the time when the echocardiography was performed. Analyses of the echocardiography data were performed offline by an investigator blinded to the APCO data. To minimise bias, the sonographers performing the study did not analyse the CO data.
APCO monitoring
The FloTrac sensors were connected to the radial arterial catheters of the patients. The output of the arterial pressure signal was fed into the Vigileo monitor where the waveform could be analysed (software version 1.10). Patient demographic data, including gender, age, body weight and height, were entered. The sensor was placed at the same level as the right atrium before pressure equilibration (zeroing). After checking the arterial waveform fidelity, APCO measurements were initiated. The CO data was automatically averaged and updated every 20 seconds.
Echocardiography
TTE examinations were performed using a 1.5-3.5 MHz transducer on a GE Vivid 7 or Vivid i ultrasound machine (GE Vingmed Ultrasound AS, Horten, Norway). CO was calculated from the product of HR and stroke volume, the latter of which was estimated from the LVOT cross-sectional area and flow. LVOT cross-sectional area was calculated from the diameter obtained from the parasternal long axis view during peak systole [crosssectional area=π(diameter/2) 2 ]. LVOT velocity time integral, which represents the summation of all velocities per heart beat, was obtained using pulsed wave Doppler from the apical view with the ultrasound beam parallel to the flow. The velocity time integral of five beats were averaged to estimate CO. If respiratory variations were >10%, the average of 10 beats, covering both inspiration and expiration, were used. Statistics Unless otherwise stated, all data were expressed as mean ± SD. Class comparisons were made using two-tailed Student's t-test. Pearson productmoment correlation was used for regression analysis. Bias and precision statistics were performed according to Bland and Altman 8 . Bias is defined as the mean of the differences between the two measurements [bias=Σ(APCO-CO Echo )/N], and precision is the SD of the differences. Limits of agreement (LOA), which represent the 95% confidence interval of the bias, is the range enclosed by bias ± 1.96 SD. To study the effect of the size of CO on bias, biases were corrected for the corresponding CO by dividing the bias by the mean CO (corrected bias=(APCO-CO Echo )/ [(APCO+CO Echo )/2]) and expressed as a percentage. Measurements errors were calculated based on the methods provided by Critchley and Critchley 9 . Serial measurements (changes in CO) for both techniques were correlated against each other by linear regression. P <0.05 was considered statistically significant. The analyses were performed in two stages: 1) all 53 patients were included; and 2) after excluding patients with arrhythmias or severe aortic stenosis (n=42). Only one pair of measurement points (APCO and CO Echo ) per patient were used in all bias and precision analyses. Table 1 summarises the characteristics of the patients. Most of the patients (49/53) enrolled displayed symptoms of shock requiring catecholamine support. The majority of patients had septic shock (31/49) and two had mixed (septic and cardiogenic) shock. One had obstructive shock due to massive pulmonary embolism and another had haemorrhagic shock due to aortic dissection.
RESULTS
All patients
The mean APCO and CO Echo were 5.65± 2.0 l/minute and 5.30±1.60 l/minute respectively (P=0.323). A significant correlation was observed between the APCO and CO Echo readings (P <0.001) ( Figure 1A) . The bias and precision (mean ± SD) between the two devices (APCO and CO Echo ) was 0.35±1.35 l/minute. The LOA (bias ± 1.96 SD) was -2.3 to 3.0 l/minute ( Figure 2A ). The percentage error was 49.3%.
Selected patients
Five patients had atrial fibrillation during the TTE examinations and another six were discovered to have aortic stenosis by TTE. When these patients were omitted from the analysis, the APCO and CO Echo were 5.43±1.83 l/minute and 5.41±1.63 l/minute (n=42). The two methods displayed good correlation (r=0.90, P <0.001) ( Figure 1B) . The bias was 0.02±0.80 l/minute and the LOA was -1.55 to 1.59 l/minute ( Figure 2B ). The percentage error was 29.5%. The Bland and Altman plot with corrected biases (bias/mean CO) demonstrated that the percentage errors at any given CO were relatively uniform (mean bias and precision was -0.7±14.1% of the CO) ( Figure 3 ). Changes in CO for two consecutive days appeared to correlate well between the two methods (r=0.86, P <0.001) ( Figure 4 ).
Effects of gender, body surface area, age and heart rate on bias
There was no significant gender difference in the mean biases (male vs female: 0.20±0.73 vs -0.34±0.82, P=0.069). There were also no significant correlation between the bias and either body surface area or age. The correlation coefficients (r) were 0.16 and 0.02, respectively (P >0.05 in both cases). There was a weak but significant correlation between the bias and heart rate, with a tendency for the FloTrac/Vigileo to overestimate CO Echo at high heart rates (P=0.028) ( Figure 5 ).
DISCUSSION
We compared the CO measurements between FloTrac/Vigileo (v 1.10) with TTE in the intensive care setting. All patients in the study required CO monitoring and were mostly in either septic or cardiogenic shock. When pooled together, our results demonstrated that the comparability between APCO and CO Echo was poor, and the bias and LOA were similar to previous studies 7,10-25 . However, after excluding patients with atrial fibrillation and aortic stenosis, APCO and CO Echo compared favourably with each other in this cohort. The bias was small (0.02 l/minute) and the percentage error was 29.5% which was within the 30% limit of clinical acceptability as suggested by Critchley and Critchley 9 . The percentage error remained relatively uniform at any given levels of CO. APCO seemed to register a higher CO than TTE at high heart rates but the correlation was weak. Gender, age and body surface area did not affect the level of bias. In repeated measurements for two days, APCO and CO Echo were able to track each other reasonably. We have chosen to compare FloTrac with Doppler TTE for several reasons: 1) TTE is routinely performed on patients with shock to determine the cardiac and fluid status in our unit; 2) TTE is known to be an accurate and robust technique for CO measurements in most conditions in the critical care setting, and is comparable to thermodilution 26 ; and 3) TTE is the modality of choice to identify patients with significant aortic valve pathology.
Previous studies
A number of studies have compared FloTrac/ Vigileo with other methods, e.g. PAC thermodilution and transpulmonary thermodilution ( Figure 6) 18 Sakka 2007 19 Biais 2008a 20 Biais 2008b 21 Biais 2008b* 21 Compton 2008 22 Mehta 2008 23 Zimmermann 2008 11 Biancofiore 2009 ITD   ITD  ITD  ITD   ITD   ITD   ITD   ITD   ITD  ITD   TPT   TPT   TPT   TTE   TTE   TOE The percentage error was large (40%). The poor comparability between the two methods may be due to the rather small sample size of the study (n=10). Another aspect of Concha's study was their use of LVOT area together with aortic blood flow, instead of LVOT blood flow, to calculate the CO. It is noteworthy that the aortic blood flow does not equate LVOT blood flow, especially in conditions such as aortic stenosis and low cardiac output. Whether or not this contributed to the large discrepancy in their study is unclear.
Among the various studies, there are only three studies that compared FloTrac/Vigileo with another device in the intensive care setting 18, 19 . McGee et al compared APCO with the intermittent thermodilution method in a total of 84 patients (69 surgical; 561 data pairs) requiring cardiac output monitoring 18 .
Despite the heterogeneity of the study population, these authors found that APCO was comparable with the intermittent thermodilution method. On the other hand, Sakka et al compared APCO (v 1.07) with transpulmonary thermodilution in 24 patients (72 data pairs) with septic shock, all with abdominal sepsis, and concluded that APCO was not as reliable as the latter 19 . Compton et al pooled 324 data pairs obtained from 25 haemo-dynamically unstable patients (variable number of measurements per patients) when comparing APCO (v 1.10) with transpulmonary thermodilution and found that APCO displayed limited agreement with transpulmonary thermodilution and consistently underestimated the CO 22 . The results from these studies, including ours, were not in absolute agreement. The main reasons could be attributed to the differences in study design (variable number of measurements per patients), reference devices, version of the softwares and the composition of the study cohort.
Sources of variability in previous studies
Random errors (noises) were mostly responsible for precision (SD). Bias and precision analysis attempts to eliminate 'random noises' by taking the differences of the readings. Yet there are situations where noises cannot be completely eliminated due to different algorithms used by the devices. For instance, while aortic stenosis or arrhythmias have little impact on thermodilution cardiac output measurements, both conditions may distort the arterial pressure waveform (shape and amplitude) and results in erroneous APCO readings. For example, Lorsomradee et al demonstrated that severe aortic stenosis, severe aortic insufficiency and the use of a balloon pump widened the gap of APCO and PAC-continuous CO measurement 7 .
In the present study, we also found that inclusion of patients with severe aortic stenosis and atrial fibrillation resulted in larger LOA (Figure 2) .
Many studies included more than one data pair per subject in the study. This approach assumes every data pair from each patient are independent from each other, which is not true. Further, the standard Bland-Altman method was not designed for repeated measures (pooled data) 27, 28 . The inclusion of multiple and variable number of measurements per subjects may single out and exaggerate certain patients' conditions resulting in a significant bias in the study. An extreme case can be found in Opdam et al where a total of 208 measurements were made from six patients, and 158 of these measurements were collected from just one patient 29 . The inclusion and pooling of data acquired peri-and intraoperatively would have the same problem. Small bias differences were commonly observed between perioperative and intraoperative data 10, 25 . Loromradee et al showed that the CO and stroke volumes measured by both continuous thermodilution (PAC) and FloTrac/ Vigileo were altered significantly by sternotomy suggesting that pooling of these kinds of data may conceal the accuracy of the devices 7 .
Factors affecting the bias and precision between CO Echo and APCO
The present study demonstrated that the discrepancy between APCO and CO Echo was great in patients with irregular rhythm. In this study we used the 20 second averaging method which was about the same duration over which the CO Echo was derived. Apparently this 20 second duration was not enough to average out the effects of irregular rhythm. Further studies are required to confirm whether or not a longer averaging algorithm yields better comparability.
Although APCO relies on demographic data (body height and weight, gender and age) in the prediction of CO, we showed that these factors did not confound the bias between CO Echo and APCO. Mayer et al also found that the biases and percentage errors between APCO and thermodilution were similar between obese and non-obese subjects 30 . The present study suggests heart rate seemed to have a small effect on the bias between CO Echo and APCO, with APCO slightly overestimating CO Echo at high heart rates. However, there were only two patients with heart rates above 140 bpm in our study ( Figure 5 ). These two patients had septic shock with a high output state, and presumably had low systemic vascular resistance (SVR). SVR has been reported to alter the bias obtained between APCO and thermodilution with greater bias being observed at low SVR in patients with liver cirrhosis 20, 24 . Whether or not heart rate per se or SVR affects the APCO readings remains to be clarified by a larger study. It would not be surprising if either factor leads to a larger bias because rapid heart rate distorts arterial waveforms and SVR affects arterial compliance.
Strengths and limitations
There were several strengths in our study. First, we only included patients who were clinically indicated to have their CO monitored continuously. As anticipated, most of these patients had either septic shock or cardiogenic shock, and this is the population in the general intensive care unit which is more than likely to have CO monitoring. The validation of FloTrac/Vigileo in this group is therefore useful. Second, we include only one pair of data points per patient in the study to avoid sampling bias. Third, echocardiography was used to identify covert aortic valve pathology. Comparisons were made in the same cohort with and without these valvular pathologies.
On the other hand, several limitations can be identified in the present study. First, we failed to study the effects of systemic vascular resistance and vasopressors (or catecholamines), both of which have been shown to affect APCO readings 16, 20 . In a study involving haemodynamically unstable patients, Compton et al showed that noradrenaline infusion did not affect the bias (APCO vs PiCCO) albeit higher doses resulted in larger percentage errors 22 . The tone (or compliance) of blood vessels can alter the pressure waveform, it is therefore not surprising that agents that alter the status of the blood vessels would alter the waveform and hence the accuracy of FloTrac/Vigeleo. Second, we did not know the 'true' CO of the patients. While TTE is an accurate and a robust method for measuring CO, technical variations between studies (due to patients' positions, ventilation and operators' techniques) were inevitable. These variations manifested themselves as random noise in the study and partly accounted for the observed percentage errors.
Conclusion
The present study shows that APCO had a good correlation with CO Echo , and the bias between the two methods was acceptable. Such clinical acceptability is conditional upon exclusion of patients with significant aortic stenosis and arrhythmias. We recommend that 1) the performance of echocardiography to exclude these conditions before the use of FloTrac/Vigileo; and 2) the cardiac rhythm should be checked regularly before accepting the APCO measurements. If these measures are taken, in our opinion, the two methods are clinically comparable, and APCO is clinically acceptable in general intensive care unit patients who require CO monitoring.
